Phase Ⅱ Study of Adductor Canal Block With HR18034 for Postsurgical Pain Management

Phase 2 Unknown 89 enrolled Shanghai Hengrui Pharmaceutical Co., Ltd.

RandomizedParallel-groupQuadruple-blindSupportive care

Summary

Phase Ⅱ, randomized, double-blind, comparator-controlled study to evaluate the efficacy, safety and pharmacokinetics of single injection adductor canal block with HR18034 for postoperative pain management compared with ropivacaine.

Timeline

Start: 2022-10-20
Primary completion: 2024-12
Completion: 2024-12

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	HR18034	Unknown	190 mg	Other
Subject	HR18034	Unknown	285 mg	Other
Subject	HR18034	Unknown	380 mg	Other
Subject	Ropivacaine	Other / unclassified	50 mg	Other
Subject	Ropivacaine	Other / unclassified	75 mg	Other
Subject	Ropivacaine	Other / unclassified	100 mg	Other

Indications

No indication recorded.